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Imino Transfer Hydrogenation Reductions.  
Professor Martin Wills, The Department of Chemistry, Warwick University, CV4 7AL, UK. 
Tel +44 2476 5230, Fax +44 2476 5230, email: M.wills@warwick.ac.uk  
Abstract: This review contains a summary of recent developments in the transfer 
hydrogenation of C=N bonds, with a particularly focus on reports from within the last 10 years 
and asymmetric transformations. However earlier work in the area is also discussed in order to 
provide context for the more recent results which are described. There is strong focus on the 
Ru/TsDPEN class of asymmetric transfer hydrogenation reactions originally reported by 
Noyori et al., together with examples of their applications, particularly to medically-valuable 
target molecules. The recent developments in the area of highly active imine-reduction 
catalysts, notably those based on iridium, are also described in some detail. There is a 
discussion of diastereoselective reduction methods as a route to the synthesis of chiral amines 
using transfer hydrogenation. The recent development of methodology for positioning 
reduction complexes within chiral proteins, permitting the generation of asymmetric reduction 
products through a directed modification of the protein environment in a controlled manner, is 
also discussed.  
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1 Introduction. 
In recent years a significant amount of research has been carried out on the transfer 
hydrogenation of C=N bonds using complexes based on a range of metals but most frequently 
on the use of ruthenium, iridium and rhodium. Many of the advances have been in the use of 
asymmetric catalysts for this process, and several of these are closely related to similar catalysts 
for asymmetric hydrogenation using hydrogen gas as a reagent. In addition the combination of 
organometallic reagents with organocatalysts has been developed, as has the use of purely 
organocatalytic processes. A large number of synthetic applications, notably to pharmaceutical 
targets, have been reported.  
The objective of this review is not to recount the early history of the transfer hydrogenation of 
C=N bonds, including asymmetric versions, because this has been reported adequately in a 
range of other reviews.[1-14] In addition, the mechanisms of the reactions have been discussed 
in detail. Hence whilst some recap is valuable in order to set the newer results into appropriate 
context, this review will focus primarily, although not exclusively, on newer developments in 
this area reported in the last 10 years, i.e. since and including 2005. There will also be a focus 
on the applications of C=N reduction which have been reported and the development of 
asymmetric methods and catalysts for this process. These will be distinguished by abbreviations 
for transfer hydrogenation (TH) and asymmetric transfer hydrogenation (ATH). The reducing 
agents (hydrogen sources) in the great majority of cases are either an alcohol (normally 
isopropanol –IPA – which is also used as the solvent), a combination of formic acid and 
trimethylamine (FA/TEA – usually used as a 5:2 azeotrope) or an aqueous solution of sodium 
formate (SF). The review will not cover hydrosilylation reactions, although some excellent 
reports have appeared in this area.[15-17]  Organocatalysis, not involving a metal catalyst, is 
covered elsewhere in the volume and therefore not featured here although some reviews that 
have been published on this are highlighted for context.[18,19]   
2  Organometallic catalysts for the transfer hydrogenation of imines. 
2.1  TsDPEN /Ru and related organometallic catalysts.  
Chemical methods for the TH of C=N bonds and notably the reduction of imines to amines 
have been known for many decades, early examples being the use of ruthenium complex 
Ru3(CO)12 [20] and [RuCl2(PPh3)].[21] In both cases, IPA was used as the reducing agent and 
a base was used to activate the catalyst. Relevant to the latter example, it was later demonstrated 
that [RuH2(PPh3)] is an active TH catalyst which did not require added base.[22,23]  
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One of the most significant developments in imine ATH was reported in the mid-1990s when 
Noyori et al. reported their results on the use of the now very well established ruthenium 
complexes 1 of monotosylated 1,2-diamines in the asymmetric reduction of imines (Figure 
1).[24] This important paper contained the first report of the application of this highly practical 
asymmetric catalyst for imine ATH. Of the series of catalysts tested, trans-1,2-diphenylethane-
1,2-diamine (DPEN) formed the basis of the ligands, which could be created by converting just 
one of the amine groups to a sulphonamide- with a range of sulphonamides proving to be 
compatible. Of these, the monotosylated derivative (TsDPEN) is now probably the most widely 
used in the field. There is also some scope for variation of the η6-arene ring and its selection 
can significantly influence the activity and selectivity of the reductions. 
Although a range of C=N bond-containing substrates were described, Noyori et al.’s study 
revealed cyclic imines such as dihydroisoquinolines (DHIQs) and dihydro-β-carbolines 
(DHBs) to be excellent substrates. The reducing agent in this case was FA/TEA and an organic 
co-solvent was required. This paper contained an account of the application of the methodology 
to the synthesis of precursors of the Merck drug MK-0417.  The reduction of acyclic substrates 
reported at this time proceeded in lower enantioselectivity however (Figure 1; note that the 
general reaction outcome using the (R,R)-configuration catalyst is illustrated, examples were 
given of the use of both catalyst enantiomers). 
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This initial result generated a great deal of future work in this area; many examples of 
applications of related reductions of substrates containing C=N bonds have since been reported 
and will be described later.   
Closely related catalysts containing TsDPEN and related ligands with alternative metals – most 
significantly rhodium (III) and iridium (III) - have also been developed. In these examples, an 
η5-pentamethylcyclopentadienyl(Cp’) replaces the η6-arene in order to maintain an 
isoelectronic structure. Although Rh(III) complexes of TsDPEN were first used in the ATH of 
ketones, Baker reported, in 1999, the use of complex 2 in imine reduction. In the majority of 
cases the selectivities were high, although some differences to the Ru(II) catalysts were also 
observed; for example the reduction of aromatic-substituted (as opposed to alkyl-substituted) 
and acyclic imines gave products of very low ee (Figure 2).[25] The commercialisation of the 
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Rh(III) derivatives was undertaken by a team at Avecia, who developed optimised approaches 
to a range of reductions of phosphinoyl-substituted imines, described in a later section.[26] 
Progress has been made towards an understanding of the mechanism of reduction of imines 
using Ru(II) complexes of TsDPEN and a number of kinetic studies have been carried 
out.[27,28] Bäckwall et al. demonstrated that the protonated imine was required for reduction, 
by using the stoichiometric hydride reagent for the reduction [29]; whilst the iminium salt of a 
cyclic imine was reduced by this hydride, the unprotonated imine was not.  
N-Alkylated derivatives of the catalysts, i.e. 3a-3f also work well in the reductions of imines, 
provided that benzene is used as the η6-ring on the Ru(II).[30] In these studies the imine 
substrates were reduced within hours whilst the ketones required one or more days. 
Interestingly the N-methylated complex 3a was slightly more active than the ‘parent’ complex 
1 (Figure 3),[31] whilst the more hindered complexes were less active. In all cases the same 
product enantiomer was formed from each ketone and imine substrate irrespective of the 
catalyst used, suggesting a common mechanism between all the complexes. However it is 
noteworthy that the hydride is delivered to a different relative substrate face for the ketone 
((R,R)-catalysts give R-configuration alcohol) compared to the imine ((R,R)-catalysts give (S)-
configuration alcohol)  The requirement for a stabilising H-bond between the NH of the ligand 
and the O atom of the ketone C=O group during the reduction of ketones is now well-
established (Figure 4). It would appear that a single alkyl group on the N atom of the ligand 
within the catalyst does not hinder this interaction.[32]
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Wills et al. subsequently demonstrated that catalyst 4, derived from a modified TsDPEN 
containing a dimethylated amine, was competent in the reduction of imines but not of ketones. 
The same was the case with the N-methylated ‘tethered’ complex 5.[33] This result provided 
evidence that the frequently-cited cyclic N-H hydrogen bond to the ketone which is essential 
for its reduction,[34] is not essential in the case of imine reduction (Figure 4). On the basis of 
these results, it was proposed that imine reduction by Ru(II)/TsDPEN complexes proceeds 
through an ‘open’ (i.e. non-cyclic) transition state (Figure 4), which would account for the 
major product enantiomer observed whilst permitting the established edge/face stabilising 
interaction to operate between the H atoms on the η6-arene ring of the catalyst and the aromatic 
ring of the substrate.[3,4] This would be analogous to observations previously reported on 
certain hydrogenation reactions of imines, where an ionic hydrogen transfer is proposed.[35-
37] 
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A series of reductions of imines to tetrahydroisoquinoline and tetrahydro-β-carboline alkaloids 
in aqueous media was reported by Pihko et al.[38] In this work, the addition of lanthanide salts 
resulted in improved selectivity and activity in the reductions, and the authors also proposed 
an ‘open’ transition state for the hydrogen transfer– in this case aided by the lanthanide as a 
co-catalyst (Figure 5).  
Subsequent molecular modelling studies by Václavik, Šot, Kuzma et al. also provided support 
for an ionic pathway for the reduction of protonated imines but with an additional stabilising 
interaction in the form of a hydrogen bond from the N-H bond from the substrate to the SO2
group – serving to improve the direction and control of the reaction (Figure 6).[39,40] 
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A detailed study by the same group, using by NMR, FTICR MS and vibrational circular 
dichroism, demonstrated that the use of different bases in place of the commonly-used 
triethylamine influenced significantly the activity and selectivity of imine reductions. A key 
finding was that the protonated base appears to interact with the hydride form of the catalyst 
during the reduction, probably via a hydrogen bond to the SO2 unit – in addition to the other 
predicted interactions of the protonated substrate.[41,12] Hence the selection of base can have 
a significant moderating effect. In further computational studies on a related catalyst for ketone 
and imine reduction, it was demonstrated that the iminium cation reacts more quickly than the 
imine. A good catalyst for transfer hydrogenation is concluded to be one which ‘combines an 
electrophilic metal centre and a nucleophilic NH group’.[42,43]  
2.2  Synthetic applications of Ru/TsDPEN and related catalysts. 
ATH of dihydroisoquinolines was reported initially by Noyori and an early observation was 
that the reaction was lower enantioselective for substrates containing a 1-aryl group. Vedejs et 
al.  reported several improvements to the reduction of these substrates (Figure 7).[44] 
Significantly, this group found that the ortho-bromophenyl substrate gave the best result (up to 
98.7% e.e.) of a series of substrates tested in this application. A valuable example of an 
application was the asymmetric synthesis of (S)-(-)-cryptosyline 6 which was formed in 83% 
e.e. upon ATH. The e.e. could however be raised to >99% through subsequent 
recrystallization.[45] This was a key step of a total synthesis of  the neuromuscular blocking 
agent GW0430. 
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In a further recent example of Ru(II)/TsDPEN-catalysed ATH of 1-aryl-substituted 
dihydroisoquinolines, a wide range of substrates were reduced using FA/TEA and iPrOH as 
solvent, with 1% catalyst. This series included challenging substrates with ortho-substituted 
aromatic rings.[46] In another report, 1-aryl substituted dihydrosoquinolines were 
demonstrated to be reduced in improved selectivity using a catalyst based on a borneolsulfonyl 
derivative of DPEN, compared to the more widely used TsDPEN.[47]
Significantly more reports have been published on the use of dihydroisoquinoline reduction 
where the 1-substituent is either an alkyl or a benzyl group, for which the enantioselectivity is 
generally high. Reductions of this class of substrate have led to many valuable breakthroughs. 
In many cases, the reducing agent is FA/TEA (5:2 azeotrope); one of the earliest was the report 
by Sheldon et al. giving products (intermediates in the synthesis of a series of alkaloids) in up 
to 99% e.e..[48] Likewise, Boros et al. used  an ATH with FA/TEA as reductant catalysed by 
a Ru(II)/TsDPEN catalyst for the synthesis of intermediate 7 which is itself a component of a 
more complex product containing two tetrahydroisoquinoline rings.[49] Another example is 
the synthesis of emetines by Tietze et al. (Intermediate 8) [50] and by Itoh et al. of the synthesis 
of 9.[51] Many functional groups can tolerate the use of FA/TEA in the ATH reactions, 
including esters [52] and phthalimides.[53] 
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In an excellent examples of the industrial application of this methodology, a useful comparison 
was made between asymmetric hydrogenation (i.e. with hydrogen gas –AH) and ATH 
approaches to almorexant (ACT-078573A), a dual orexin receptor antagonist variant using a 
Ru/TsDPEN catalyst scaled up to 100s of kg of substrate. This specific targeted application 
worked very well under carefully optimised conditions, particularly when the 
methanesulfonate salt of the substrate was used. The use of a 1:1 ratio of FA:TEA gave a more 
rapid reaction compared to the more-widely used 5:2 ratio, and the formation of a small amount 
of the formylated side product was observed but this was minimised during the process 
optimisation (Figure 9).[54] Following a recrystallization, 87% of product was isolated in 
99.7% e.e. on a 18 kg scale which required 17g of catalyst. 
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In another excellent example of an application, the enantioselective total synthesis of (-)-(S)-
stepholidine, a candidate for treatment of schizophrenia, was achieved through a C=N 
reduction, in >99% e.e. and 42% yield (Figure 10).[55]
Reductions of imines can also be carried out under aqueous conditions; the aqueous process 
appears to be readily applicable to dihydroisoquinoline reduction and also for dihydro-β-
carbolines (discussed in more detail later) but can be significantly enhanced by the addition of 
a silver salt and Ln(OTf)3 or a closely related salt (Sc, Y, Ce, Yb, Bi salts were tested) and 
therefore applied to more challenging substrates than would otherwise be possible (Figure 
11).[38] The use of a combined methanol/water solvent also provides some advantages in the 
most difficult cases. The acceleration of the reduction through an ‘open-TS’ hydride transfer 
mechanism using a lanthanide cation as a Lewis acid has been described above (Figure 5).  
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In a comparative study, two optimized approaches to mivacurium chloride (and other skeletal 
muscle relaxants) was reported. (R)-5′-Methoxylaudanosine was prepared by ATH of a 
dihydroisoquinoline and the process was compared to a resolution strategy.[56] 
Several studies on the various parameters which influence the ATH of DHIQs have been 
reported,[57,58] and reductions have been monitored by NMR spectroscopy in order to 
generate valuable kinetic data.[59,60] A study of five substrates revealed that rate and e.e. are 
substrate dependent[61], whilst the effect of the η6-aromatic ring revealed that 
hexamethylbenzene series is very slow; two DHIQ substrates were investigated.[62] The ATH 
of imines (and ketones) using tethered Rh(III) catalysts has also been reported.[63] 
Cyclic dihydro-β-carbolines, originally exemplified by Noyori,[24] are another class of 
substrate popular for ATH reactions, since their reduction products are represented in 
biologically active targets. Examples of targets which can be prepared through reduction in the 
popular FA/TEA system (often together with a cosolvent) are illustrated in Figure 12. [52,64] 
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Iminium salts can likewise be used as excellent substrates for ATH reactions. Czarnocki et al, 
have completed a short synthesis of (R)-(+)-crispine A 10 through the reduction of the iminium 
salt 11,[65,66] and this has been extended to further iminium substrates (Figure 13) which have 
been successfully reduced.[67] The compounds could be purified to enantiomeric purity using 
a recrystalisation after the reduction. 
The use of a Ru(II) catalyst containing a proline-derived tetrazole ligand has been reported in 
a synthetic application; the reduction of an iminium cation en route to (S)-(-)-lennoxamine 
(Figure 14). The study provided an interesting contrast between the use of both ATH and AH 
reduction methods, the selection depending on the metal used.[68] 
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In addition, the synthesis of new mono-N-tosylated diamine ligands based on (R)-(+)-limonene 
and their application to ATH of cyclic imines and iminium salts gave good results; up to 98% 
e.e. in some cases.[69] Reductions of iminium salts using 1.2 mol% of a Ru(II) catalyst, using 
sodium formate with cetyltrimethylammonium bromide (CTAB) in aqueous solution, with the 
addition of silver hexamethylantimonate, have been described.[38] 
ATH can be used to form sultams (Figure 15) in a very efficient and selective reduction using 
Ru complexes [70] and indeed this was one of the first reported applications of the 
Ru(II)/arene/TsDPEN complexes. Analogous Rh(III) complexes can also be used.[25] 
Dendrimer and polymer-supported catalysts can be employed in the ATH of sultam 
precursors,[71,72] including examples where the supporting material has sulfonyl groups and 
therefore assists reactions in water.[73] The synthesis of an amphiphilic polystyrene-type 
immobilised TsDPEN ligand and its application in ATH of cyclic sulfonimines has been 
reported (Figure 16).[74] 
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Acyclic N-sulphonylated imines can also be reduced by ATH although selectivities are 
lower.[72] 
Other polymer-supported systems for C=N ATH feature polymer microspheres functionalized 
with a chiral ligand by precipitation polymerization[75] and the use of recyclable 
organoruthenium-functionalized mesoporous silica; reduction of quinolines in up to 99% e.e. 
was reported.[76] The efficient ATH of N-sulfonylimines on water using a Rh-imido complex 
preceeded with higher reactivity and enantioselectivity compared to the homogeneous reaction. 
Interestingly, the reactivity appears to depend on stirring speed of the reaction as well as other 
experimental factors.[77] The ATH of imines and ketones under aqueous conditions has been 
reviewed in detail.[78,79] 
As well as the more established TsDPEN ligand derivatives, proline-derived, water soluble 
arene Ru(II) catalysts containing sulfonylated ligands have been used for ATH of α-aryl 
ketones and imines in aqueous solution.[80] The ligands in Figure 17 were prepared and 
incorporated into Ru(II) aqua complexes (i.e. cationic) – the effect of the pH in aqueous 
reductions was also studied and was optimal at about 8-9 with these catalysts. 
Another example of the reduction of ketones and imines with a novel water-soluble chiral 
diamine 12 as the ligand in neat water has been reported (Figure 18).[81] Cyclic imines were 
reduced in high e.e. 
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The combination of methanol and water gives improved results in some cases.[38] The use of 
Rh/TsDPEN catalysts on cyclic imine in a mixture of MeOH and water gives the highest rates 
e.g. reduction in 20 min for 98% conversion, whereas water or MeOH alone takes at least 300 
minutes for similar conversion.[82] In a detailed paper on the use of crosslinked polystyrene, 
the polymer supported reagents can reduce benzyl amines, in FA/TEA/DCM in up to 93% 
yield; Ru(II) catalysts gave the best ees. An amphiphilic version containing some sulfonic acid 
groups in water with sodium formate also reduced cyclic imine in good efficiency.[83] 
Further examples of supported catalysts used for ATH of imines include those based on
recyclable silica,[84] functionalised MCM-41,[85] siliceous mesocellular foam[86] and 
magnetic mesoporous silica. In the latter case the reusable immobilized catalyst exhibited high 
activity and enantioselectivities in the ATH of imines in FA/TEA. It could be separated 
mechanically using an external magnet to facilitate ready recycling.[87] 
The enantioselective synthesis of α-trifluoromethyl arylmethylamines by Ru(II)/aminoindanol 
ATH is very efficient and gives products in high yield and e.e. (Figure 19). Several ligands 
were used and tested and a good number of examples were reported, including an application 
to the synthesis of an analogue of a plant disease control agent.[88] 
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Ru(II)-catalysed ATH of α-trifluoromethylimines was also achieved using TsDPEN-based 
catalysts under aqueous conditions (Figure 20).[89]  
Several reports have recently appeared describing the ATH reduction of cyclic sulfamidates 
and sulfamides, following the report of this in 2010.[90] The synthetic routes to key substrates 
and their reductions by Rh(III) catalysts are shown in Figure 21. In all cases the ees of the 
reductions were excellent, and the reduction forms the basis of an efficient synthesis of 
enantiomerically enriched 1,2-aminoalcohols and diamines.[91]
The reduction of this classs of substrate can be extended to a dynamic kinetic resolution (DKR) 
process with C=N reduction coupled to racemisation of the adjacent stereocentre. Of the Ru, 
Rh and Ir catalysts tested, the Rh catalyst gave the best results (Figure 22). The resulting 
compounds could be converted into other products through SN2 ring-opening using phosphorus 
and nitrogen nucleophiles. Typically the reductions exhibited a selectivity of>20:1 in favour of 
the cis- product, and ees were typically 94-97% but up to 99% e.e. in a number of cases. An 
exception was for more hindered ortho-substituted substrates e.g. R1=R2= ortho-ClC6H4 the 
e.e. was only 22%.[92] 
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The stereoselective synthesis of 4-substitued cyclic sulfamidate-5-carboxylases can be 
achieved using this process of coupled ATH/DKR (Figure 23) and this method has been applied 
to the synthesis of (-)-epi-cytoxazone and the taxotere side-chain. The cis- isomer was formed 
in high selectivity; typically >25:1. A wide range of examples were reported, with 3 and 4-
substituted aromatic groups, the ees were up to 99% in many cases and generally >95% e.e. 
An example with cyclohexyl was less selective (Figure 23).[93] 
The application could be extended efficiently to 5-phosphonate-containing substrates. In some 
cases both the de and e.e. were >99% (Figure 24).[94] 
Related work on the reduction of two C=N bonds sequentially has been reported. In this case 
the Ru(II) catalyst was first used and gave good results. Preferential reduction of one C=N is 
observed but the other can be stereoselectively reduced using lithium borohydride; the products 
were transformed into chiral diamines (Figure 25).[95] 
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Asymmetric aziridines can be prepared by ATH of an azirine; this was one of the earliest 
reported applications of the use of Ru(II) complexes, achieved using a bicyclic amino alcohol 
ligand (Scheme 26).[96] 
The application of Rh(III) systems to the reduction of N-phosphinoyl imines has been described 
in depth by researchers from Avecia, who were able to obtain some very valuable insights into 
the mechanism of the reaction and requirement for removal of carbon dioxide during the 
reaction.[26] In recent related work, Guijarro et al. described the use of chiral beta-amino 
alcohols as ligands for the Ru(II)-catalyzed ATH of phosphinyl ketimines. It was demonstrated 
that the reaction was possible using cis-amino indanol (CAI) as ligand for the catalyst. A 
number of amino alcohols were tested but CAI was the best of the series (Figure 27). Most of 
the studies were conducted on acetophenone-derived imine but in examples where Ar=Ph, 
R=Et gave a product of 82% e.e. and Ar=pClC6H4, R=Me gave one of 80% e.e.[97] 
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In early work, Lassaletta et al. described a DKR reaction coupled to the formation of primary 
amines.[98] In a related process, an efficient ATH reaction for the synthesis of an advanced 
intermediate to a drug for the treatment of human papillomavirus infections, has been reported 
(Figure 28). This involves an interesting exo– C=N reduction in an in-situ process. The 
formation of an imine followed by a reduction using a Ru(II)/BINAP complex was also 
investigated, as was a diastereoselective method using alpha-methylbenzylamine as a directing 
group.[99] 
A similar reduction towards a primary amine intermediate was reported by scientists at Merck 
(Figure 29). The target in this case was the HCV NS5a inhibitor MK-8742, and a key step was 
a highly enantioselective ATH of a C=N bond. Of the catalysts investigated, the best one 
proved to be the tethered catalyst reported by Wills et al. The synthesis of the complex target 
requires simple starting materials and just nine linear steps for completion.[100] 
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Also in earlier work, Wills et al. described the formation of C-N bonds in a one-pot ATH 
starting from Boc-protected amines.[101,102] This type of process was applied in an 
impressive intramolecular ATH reaction in a key step to the dual orexin inhibitor molecule 
Suvorexant (MK-4305) (Figure 30).[103] This excellent detailed paper on reductive amination 
employed Ru(II)/TsDPEN catalyst in the reductions, and the best results were obtained using 
a derivative containing a very hindered aromatic group on the sulphonamide unit. The 
operation of the ‘open’ transition state for hydride transfer to the imine is described. The paper 
contains details of extensive investigations into the effect of excess carbon dioxide on the 
reaction; purging this from the reaction gives better rates. The significance of the formation of 
two diastereoisomers of the hydride form of the catalyst, which has been previously observed 
for this type of catalyst, was also discussed in some depth.  
. 
Heteroaromatic substrates have been productive targets for both TH and ATH reactions. 
Quinoline, and isoquinolium salts can be reduced by Ru(II) and Rh(III) catalysts by 
ATH.[104,105] Chemoselective reductions of quinolines were achieved by TH using IPA with 
an iridium catalyst (Figure 31).[106] 
N
R
N
H
R
cat. [Cp*IrCl2]2
IPA, H2O
reflux
Figure 31
The importance of Ph-regulation for the TH of quinoxalines with a Cp*Ir/TsEN catalyst in 
water has been demonstrated; the reduction using HCO2Na. at ca pH 5.5 (regulated with a 
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buffer) is shown to give the highest rates.[107] In another report, a dramatic effect of added 
iodide was shown to influence TH of a number of N-heterocycles (quinolines, isoquinolines 
and quinoxalines) when a Cp*Ir catalysts was employed for their reductions in FA/TEA.[108] 
However some important asymmetric examples have been reported; again pH-regulation  has 
been shown to be crucial to the successful ATH of quinolines in water with sodium formate as 
the reducing agent; the rate peaks at around pH 5.0 and formic acid with a formate buffer is 
used to regulate this. The best of a series of catalysts was a Cp*Rh complex of a p-(t-
butyl)benzenesulfonylDPEN although other ligands were also viable. Reductions were 
complete typically within 6-24h at 40 oC using 1 mol% of catalyst (Figure 32).[109] 
A similar process was reported using tethered Ru(II) catalysts (Figure 33).[110] 
A mesoporous silica-supported TsDPEN/Ru(II) catalyst has also been applied productively to 
this transformation.[76]  
2.3 Shvo-type catalysts and other classes of organometallic catalysts  
The Shvo diruthenium catalyst 13 (Figure 34) has been used in non-asymmetric ketone and 
imine reduction, and the mechanism has been studied and reported in some detail.[111-115][5] 
Catalyst 13 is also able to racemise amines,[116] which allows it to be combined in a DKR 
process with an enzyme to create enantiomerically-enriched amides.  
23 
Iron cyclopentadienone complexes have recently emerged as alternatives to Ru(II) catalysts, 
although their main focus is on ketone reduction rather than imine reduction.[117] 
Bifunctional rhenium complexes, related to the Shvo catalyst, have been used in TH reactions, 
including tests on three non-prochiral imines, TOFs up to 79 h−1 were obtained for imines. In 
common with the Shvo catalysts, DFT calculations indicated the operation of an outer-sphere 
mechanism for the reaction.[118] 
Cyclometallated complexes of Ru, Rh, Ir have been used as ATH catalysts; Some examples of 
this class of catalyst have been prepared and reported earlier, however their applications have 
now been extended to a broader range of target imines, both cyclic and acyclic (Figure 
35).[119] 
Ru–Pybox complexes have been used to achieve imine ATH in IPA; these complexes gave 
some excellent results for imine derivatives of acetophenone with products of up to 99% e.e. 
in some cases using 1 mol% of catalyst (Figure 36). There was some mechanistic discussion 
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and a number of examples were reported. In general these complexes have been used much 
more widely for ketone ATH.[120] 
A very interesting report of a nickel-catalyzed ATH of hydrazones and related substrates has 
been published. Using a complex formed from a combination of (S)-binapine and a Ni(II) 
source, with FA/TEA as the reducing agent, products of up to 97% e.e. were formed in the 
reduction (Figure 37). The reaction also works with sultams, giving products in 98-99% e.e. 
Deuterium labelling studies were also carried out, in D-FA and during the reduction, resulting 
in deuteration of the Me group and indicating that exchange could be taking place through an 
enamine.[121] 
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A bio-inspired catalyst comprised of a combined organic hydride donor with metal centre has 
been reported for TH of imines. A previously used catalyst relied on a Hantzsch ester but the 
newer derivative benefits from more readily preparation and greater accessibility. Yields are 
high for the Rh complex containing all the components and more than for the Ir complex or the 
complex containing the phenanthroline ligand alone (Figure 38).[122,123]
Several iron complexes for imine ATH have been developed by Morris et al. IPA is used in the 
reduction. Early examples of the PNNP-complexes (containing imine ligands) of iron gave 
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100% reduction of PhCH=NPh but only 5% of PhCMe=NPh.[124] Beller reported the use of 
an in situ-generated catalyst for ATH of imines with high yield and enantioselectivity (Figure 
39).[125] 
However Morris et al. later discovered that iron complexes containing a combination of one 
amine donor and one imine donor (e.g. 14) were superior catalysts for ketone and imine ATH 
(Figure 40). The researchers followed on from results which indicated that the proposed 
reduction of one C=N bond of the original ligands was important to the mechanism. They 
prepared an amine/imine ‘P-NH-N-P’ ligand first by adding one C-NH bond in a reductive 
amination process and then forming the second, C=N bond and finally the ‘third generation’ 
complex 14 (Figure 40). This new class of catalyst was effective in the rapid reduction of N-
diphenylphosphinoyl activated imines containing phosphinoyl groups in>99% e.e. (Figure 
41).[126,127] 
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Full documented details of synthesis and use, including pictures of the reaction setup have been 
published.[128] 
Very few examples of osmium-catalysed ATH reactions of imines have been reported.[129]
However one example is provided by arene iminopyridine halido complexes which additionally 
exhibit properties as antitumor agents. Four complexes were prepared and tested, giving 
reductions in FA/TEA of ca. 22-23% e.e. in each case (Figure 42).[130] 
2.4 Incorporation of TH catalysts into proteins.  
One of the significant developments within the decade leading up to this review have been the 
contributions made to the development of organometallic reagents contained within protein 
structures, relying on the asymmetric environment of the protein to generate asymmetry in the 
reductions when a simple (i.e. non-chiral) complex is added to it. Many contributions have 
been made by Prof T. Ward et al., and principally through the attachment of an organometallic 
complex of a non-chiral Ts-diamine ligand to biotin, thus allowing it to be coordinated within 
the chiral environment of a streptavidin molecule and hence an asymmetric induction 
generated. Important to this process is the ability to modify the streptavidin structure in a 
selective manner in order to optimise the reactions towards these substrates. This section shall 
examine the principle developments in this area, which is a part of a larger programme on many 
applications of metal/protein complexes. 
Following extensive work on optimising the catalysts towards the reduction of ketones, studies 
were extended to imine reductions. The illustration in Figure 43 illustrates how a component 
of the protein (i.e. a lysine side chain) can stabilise the iminium substrate during the reduction 
by an iridium catalyst which is chiral at the metal and within the chiral environment created by 
the protein. In common with other models previously described for imine ATH, the ‘open’ 
transition state for the reduction is proposed. This is based on observed results and X-ray 
crystallographic evidence; the S112A variant containing the Ir/TsEN (EN = ethane-1,2-
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diamine) complex attached to biotin was isolated and the X-ray crystallographic structure was 
obtained.[131,132] 
The streptavidin variant is generated as a part of a screen of modifications.  In this work, no 
asymmetric induction was obtained without protein, and the wild-type streptavidin (Sav) gave 
a reduction product of up to 57% e.e. (R). However the S112A mutant of Sav gave an amine in 
up to 96% e.e. (R) and in other cases (e.g. S112K mutant) the enantioselectivity could even be 
reversed. In addition up to 4000 turnovers of the synthetic enzyme could be achieved.[133-
137] Computational and molecular modelling has been applied to this process to aid 
optimisation.[138] 
In parallel work, the synthetic enzyme has been gradually refined through further optimization. 
In a later paper,[139] human carbonic anhydrase II, was combined with a sulfonamide derived 
from pyridine/IrCp* to create a catalyst for the ATH of imines. The X-ray structure of a 
derivative was used to improve the catalytic performance, ultimately achieving 68% e.e. A 
ribonuclease has also been used as the basis of an artificial amine reductase. In this case the 
incorporation of a Cp*Ir complex gave an efficient and selective artificial enzyme for imine 
reduction.[140]  
With the most advanced streptavidin variants, the strategy in which a racemic catalyst is 
converted to a chiral-at-metal complex and then assisted further by residues in the chiral 
protein, have led to the development of both R and S- selective synthetic enzymes for imine 
reduction. Extensive kinetic data has been obtained for these new synthetic enzymes, and 
computer modelling of the complex structures (which contain four interacting subunits) serves 
to support and understand the results. An ‘induced lock and key’ where the host protein 
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structure determines the catalyst structure and the reduction selectivity, is proposed (Figure 
44).[141] 
Optimisation of a synthetic enzyme derived from human carbonic anhydrase II has also been 
achieved in a similar manner, resulting in conversion of a wild type selectivity of 70% e.e. with 
a TON of 9 to a modified variant with several residue changes which gave a product in 96% 
e.e. and a TON of 59. Again X-ray crystallographic evidence demonstrated that the piano stool 
complex was embedded within the protein; which served to influence its configuration and 
assist in the asymmetric control of hydrogen transfer.[142] An ingenious method for amine 
deracemisation can be achieved within a cascade of reactions which combines a biocatalyst 
with the synthetic enzymes created in this work.[143] Related work has been reported on 
ketones rather than imine, and several informative reviews on Ward et al.’s work have been 
published.[144-148] A related example describing the influence of an external directing group 
– in this case a homochiral phosphonic acid – on the transfer of hydride from a Cp*/Ir/TsEN 
complex to an imine, has been reported. [149] Although hydrogen gas is used as the reducing 
agent, a similar process of chirality induction takes place at the Ir complex. 
2.5 Hydrogen borrowing and organocatalysis. 
Although technically a ‘hydrogen borrowing’ reaction rather than a reduction, a C=N reduction 
is involved at a key stage to good effect in some specific applications where an alcohol is 
converted to a chiral amine. Cooperative catalysis by iridium complex and a chiral phosphonic 
acid can lead to asymmetric amines starting from racemic alcohols.[150] Likewise, the use of 
a chiral phosphonic acid with an Ir/TsDPEN complex gave a very interesting DKR and 
amination of alcohols in one process; from a mixture of four isomers, one product enantiomer 
is predominantly formed.[151] 
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In recent years, several papers have been published on the combination of an organometallic 
catalyst with a chiral phosphonic acid in order to achieve enantioselective reduction of an 
imine. This obviates the requirement for a Hantzsch base by replacing it with the combination 
of an organometallic complex and hydrogen gas. However since these involve the use of 
hydrogen gas they are technically outside the scope of this review, although a recent overview 
is highlighted [152] and one example is illustrated (Figure 45).[153] 
The direct reductive amination of aromatic aldehydes has been achieved with excellent yields 
using a gold(I) catalyst along with a Hantzsch ester as the hydrogen source under mild reaction 
conditions.[154] In another example, B(C6F5)3- is shown to act as a catalyst for the transfer of 
hydrogen from a Hantzsch ester to an imine.[155] 
3  Meerwein-Ponndorf–Verley (MPV) reductions  
The development of asymmetric MPVreactions has been described [156], notably a very 
selective system based on Al(III)/BINOL complexes has been reported (Figure 46).[157] In 
this example the ees for all products were determined although only the configuration of the 1-
phenylethylamine derivative was established. However the absolute configurations of the other 
products can inferred (but are not shown) based on the steric size difference between the 
substituents flanking the imine in the substrate. 
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In a recent example, α-silylamines were prepared by MPV-type reduction of α-silylimines This 
does produce the amines in up to 99:1 er although it is a stoichiometric rather than catalytic 
process using a chiral amine as the donor of hydride (Figure 47).[158] 
4) Reductive amination reactions. 
The Leuckart-Wallach reaction has been reported as being effective for the synthesis of chiral 
amines, with some very important contributions having been made by Kadyrov and Riermeier, 
who employed a Ru(II)/BINAP derivative to excellent effect, giving products from 
acetophenone derivatives in up to 95% e.e. [159]. The simple complex [Cp*Rh(III)Cl2]2 can 
be used to give racemic products.[160] In a recent related example, although a hydrogenation 
rather than a transfer hydrogenation, a BINAP/Pd complex was used to form products of up to 
99% e.e. in reductive amination of acetophenones using anilines (Figure 48).[161] 
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5 Diastereoselective asymmetric reductions 
A series of highly selective reactions have been reported by Guijarro et al., where a chiral 
sulfinylgroup directs the ATH of an imine, using either an asymmetric catalyst or a racemic 
one (Figure 49). Using cis-aminoindanol, very selective syntheses of amines are possible,[162-
164] and imine formation could be accelerated with microwave irradiation. 
However in later work it was found that a non-chiral ligand could also be used – the 
enantioselectivity being created by the sulfinyl group (Figure 50).[165-167] Microwave 
radiation can be used to accelerate the reaction.[168] 
The work has been applied to the synthesis of a series of heterocycles using halide-substituted 
substrates and then completing the ring synthesis using a base-promoted process, followed by 
removal of the sulfinyl group. (Figure 51).[169] 
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6 Carbene ligand-based catalysts. 
A wide range of complexes containing N-heterocyclic carbenes have been used in the TH of 
imines, and some examples are given in Figure 52, along with an indication of the typical TONs 
for some of the reductions. In many cases the turnover numbers are impressive.[170-174] The 
area has been reviewed in some depth.[175-178] 
A carbene derived from triazole was used in IPA with K2CO3 as base, for direct reductive 
amination of aldehydes with primary amines to form secondary amine products.[179] Other 
recent examples include;  i) a base-free catalyzed reduction of a series of C═O bonds and of 
the C═N bond of benzylideneaniline (>99% conversion was achieved in 48h, with 0.1 mol% 
catalyst),[180] ii) heteroditopic dicarbene Rh(I) and Ir (I) complexes containing 1,2,3-
triazolylidene–Imidazolylidene ligands, mostly tested on acetophenone but with one imine 
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example,[181] iii) Ir complexes of N-benzyl substituted N-heterocyclic carbenes where 0.5 
mol% catalyst is used with 5% KOH in IPA in reductions to give products in >99% yields[182] 
and iv) Ir(III) and Ru(II) complexes with 4-acetylbenzyl-N-heterocyclic carbenes which are 
active at reduction of C=O, C=N and hydrogen borrowing.[183] Half-sandwich Ru(II) picolyl-
NHC complexes used to reduce C=O and C=N with just 0.1 mol% catalyst have been reported; 
the catalyst has a bidentate donor containing an NHC and a pyridine donor and works well in 
reductions.[184] Similar complexes with hemilabile OMe or pyridine ligands[185] and Ru(II) 
picolyl-NHC complexes have also been reported.[186] 
7 Other non-chiral catalysts. 
Several examples of TH of imines have been reported, using a range of complexes, most 
commonly based on precious metals including Ru, Ir and Rh [187,188] Some reduction 
aminations of ketones using ammonium formate with some Cp*/Ir complexes have been 
reported; these are pH dependent with respect to rate.[189] Use has been made of a Ru 
phenylindenyl chloro di triphenylphosphine complex in catalysis. These have mostly been 
applied to C=O reduction but examples of imine reduction have also been reported.[190] A 
novel iminophosphorane-based [P2N2] rhodium complex, representing a very innovative 
catalyst system, was prepared and used to reduce C=O and C=N bonds.[191] 
Some cobalt examples have recently been published; cobalt on a heterogeneous support was 
used in TH of C=O, C=N and C=C bonds using IPA as the reducing agent.[192] A cobalt 
catalyst containing a ‘PNP’ donor structure was used in ATH of a number of imines although 
the focus was on ketones and aldehydes.[193] Nickel nanoparticles have also been used in 
imino TH.[194] Studies have been carried out on the activation and deactivation processes of 
a wide range of Cp*/Rh catalysts which have been developed as valuable supported reagents 
for C=N reductions in flow systems:[195,196]  Efficient and selective TH of pyridines to 
tetrahydropyridines and piperidines has been achieved using Cp*Rh diiodide complexes; the 
method being general and wide in scope.[197] In some cases, an amine/borane complex has 
been used as the hydrogen source for the reduction.[198] Although there are also examples of 
where a catalyst is not required.[199] 
Imine reductions with Ir catalysts have produced some very important breakthroughs in recent 
years. Xiao et al. reported a new class of cyclometallated Ir-based catalyst e.g. 15, for imine 
TH, being active at very low loadings. This has been extensively used in reductive amination 
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of ketones including carbohydrates FA/TEA.[200] It was found that the control of the pH (best 
ca. 4.8) is critical for high chemoselectivity and activity, allowing the S/C to be as high as 
10,000, and higher than in organic solvents, representing an environmentally friendly catalyst 
system with broad application (Figure 53).[201] One specific application of the catalyst has 
been to the transformation of levulinic acid into pyrrolidinones, which was achieved in high 
efficiency.[202]
The new catalyst 15 and its derivatives is applicable to the synthesis of primary amines by TH 
of ketones using sodium formate and also FA/TEA in the reductions (Figure 53). FA/TEA 
improves the results by increasing the acidity relative to ammonium formate alone, which gives 
products in lower conversions. A large number of examples are given including substituted, 
aryl and alkyl. Amino acids can be prepared directly from the α−keto acids. Chalcone is 
reduced to the saturated amine. α-keto ethers work well and this has been used in the synthesis 
of a antiarrhythmic agent as illustrated in Figure 53.[203] There are few other examples of the 
synthesis of amino acids through a reductive amination of this type.[204] A phenoxide-chelated 
Ir complex – 16 in Figure 54 has also been prepared and demonstrated to be capable of C=N 
bond reduction by both  hydrogenation and transfer hydrogenation via reductive 
amination.[205] 
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The iridicycle catalysts also catalyse the TH of N-heterocycles (including quinolines, 
isoquinolines, indoles and pyridinium salts) in water under mild conditions – a solution of 
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formic acid and sodium formate is employed in the reaction. TONs of up to 7500 and catalyst 
loadings as low as 0.01 mol% were used.[206]
Another potentially very important development in TH reactions is reduction of NAD+ to 
NADH by half sandwich complexes of precious metals, which has been shown to also take 
place within living cells [207-211]. It has been demonstrated that the activity of Ru/TsEN 
complexes against human ovarian cancer cells is increased by as much as 50x when non-toxic 
doses of formate are added.[211]  
8 Conclusion 
In conclusion, a very wide range of new chemistry has been developed for the transfer 
hydrogenation of C=N bonds. Several new classes of catalyst have been reported, including 
several asymmetric catalysts, and applications to a large number of target molecules, notably 
including pharmaceutical intermediates, have been reported. This area looks set for significant 
continued growth in future years. 
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